The mechanisms underlying bupropion's efficacy as an antidepressant and a smoking cessation aid are far from being fully characterized. The present study is the first to examine the effects of bupropion on visuospatial task-related parietal EEG alpha power asymmetry-an asymmetry that has previously been found to be associated with severity of depressive symptoms (i.e., the more depressive symptoms, the greater alpha power in the right vs. left parietal area [Henriques & Davidson, 1997; Rabe, Debener, Brocke, & Beauducel, 2005] ). Participants, all of whom were smokers and none of whom were clinically depressed, were randomly assigned to the Placebo group (n ϭ 79) or Bupropion group (n ϭ 31) in a double-blind study. EEG during the performance of the visuospatial task was collected before and after 14 days on placebo or bupropion sustained-release capsules. Relative to the Placebo group, the Bupropion group (especially, the Bupropion subgroup who had a positive right versus left parietal alpha power asymmetry at pretreatment) had a reduction in the parietal alpha asymmetry (driven largely by a decrease in right parietal alpha power). These findings support the hypothesis that bupropion can induce changes in parietal EEG asymmetry that have been shown in previous literature to be associated with a reduction in depressive states and traits.
had a higher accuracy than the depressed group on the DOTLOC task and, importantly, the control group showed less right versus left parietal alpha power, whereas the depressed group showed more right versus left parietal alpha power. Given that increased alpha power generally corresponds to decreased neural activity in the broad underlying cortex (Allen, Coan, & Nazarian, 2004) , the results indicated that the control group had relatively greater right parietal activation and the depressed group had less right parietal activation. Rabe et al. (2005) largely replicated the parietal asymmetry findings of Henriques and Davidson (1997) using the same DOTLOC task in a nonclinical sample of 31 women. Depressive symptoms scores were not significantly correlated with task performance, but were positively correlated with parietal asymmetry during the task-namely, more depressive symptoms were associated with less task-related right parietal activation. It is noteworthy that neither Henriques and Davidson (1997) nor Rabe et al. (2005) observed a significant association between depression/depressive symptoms and the right-versus-left frontal alpha asymmetry during the DOTLOC task, an association typically found under resting-state conditions and during emotional tasks (Schaffer, Davidson, & Saron, 1983; Stewart, Coan, Towers, & Allen, 2014) . Taken together, these two studies using the DOTLOC task support the hypothesis that individual differences in parietal EEG alpha asymmetry are not specific to clinical depression but are also present in healthy adults with variable subclinical depressive symptoms.
Given the tendency for depressive symptoms to increase subsequent to quitting smoking (Gilbert et al., 2002) , the tendency of asymmetric EEG effects of quitting smoking on EEG (Gilbert et al., 1999 (Gilbert et al., , 2004 , and the efficacy of bupropion sustained release (SR) as a smoking cessation aid (Fava et al., 2005) , the primary purpose of the present study was to characterize the effects of bupropion on parietal EEG alpha asymmetry during the DOTLOC task across 2 weeks before individuals quit smoking. The standard protocol for bupropion as a smoking cessation aid is that individuals begin using it 2 weeks prior to quit attempts (Dhillon, Yang, & Curran, 2008) . Thus, it was expected that the study would lead to a better understanding of the mechanisms of bupropion as an antidepressant and as a smoking cessation aid.
Based on the above-noted studies of Henriques and Davidson (1997) and Rabe et al. (2005) , it was hypothesized that (a) there would be a significant interaction of Treatment (Placebo vs. Bupropion) ϫ Session (Pretreatment vs. Posttreatment) in terms of parietal EEG asymmetry, but not frontal asymmetry (given the lack of association between frontal asymmetry and the visuospatial task shown in the literature), such that bupropion would significantly reduce right-versus-left parietal alpha power asymmetry across sessions, whereas placebo would not; (b) bupropion (vs. placebo) was not expected to reduce self-report depressive symptoms given the short treatment duration (14 days) in the present study and the typical 3-to 5-week lag between the onset of bupropion antidepressant medication and improved mood effects (Fabre, Brodie, Garver, & Zung, 1983; Lineberry et al., 1990) ; and (c) within the Bupropion group, individuals who exhibited higher levels of parietal EEG asymmetry consistent with depressive symptoms would benefit more from bupropion treatment (i.e., exhibit a greater reduction in parietal asymmetry).
Method Participants
Participants were habitual smokers who reported smoking seven or more cigarettes per day for at least 1 year and who expressed a desire to permanently quit smoking. They were recruited from the greater Carbondale, Illinois, area through community advertisements and received monetary compensation for their participation. Exclusionary criteria (in large part due to requirements of the parent study) included use of psychoactive drugs or medications (other than alcohol and caffeine), alcohol use Ͼ28 alcoholic drinks per week, age Ͻ18 years, non-English speaking, education Ͻ12 years, atypical sleep cycles, pregnancy or current breast feeding, uncorrected poor vision, history of seizure disorders or anorexia, current diagnosis of major depression (but not a history of depression), bulimia, organic brain disease, psychotic disorder, and hypertension. Current and history diagnoses were based on the Structural Clinical Interview.
Of the total of 127 internal-review-board consented participants, 6 dropped out after completing the initial (pretreatment) session and another 11 were excluded from analysis due to excessive EEG artifacts or collection problems. Of the remaining 110 participants, 79 were randomized to the Placebo group and 31 to the Bupropion group (the Placebo group had more participants because it aggregated other groups who, after the 2-week period described here, were further randomized to other conditions of a larger parent study involving smoking cessation but not relevant here). Participants were native English speakers except for five participants who were fluent speakers of English as a second language.
Drug Treatment
Placebo and bupropion SR capsules were identical in appearance and associated with 10-digit numeric codes unique to each participant. Treatment group membership was double blind and randomly assigned to participants. As a standard medication practice (Dhillon et al., 2008) , 150 mg bupropion SR capsules (or placebo capsules) were taken once daily for the first 3 days of the 14-day treatment, then twice daily through the remaining 11 days. Participants smoked at their regular rate during these 14 days. Treatment compliance was assured with salivary assays for bupropion SR and bupropion's three major metabolites (morpholinol, bupropion-erytho-alcohol, and bupropion-threo-alcohol).
EEG Apparatus and Data Collection
EEG was collected with 128 sensor EGI HydroCel Geodesic Sensor Nets (EGI, Eugene, OR), EGI Net Amps, and Net Station 3.2.1 software (EGI, Eugene, OR) at a 250-Hz sampling rate using the vertex (Cz) as the online reference. Although we adopted dense array EEG to achieve high spatial sampling for future source localization analyses, the present analyses used the same four electrodes (F3, F4, P3, P4) as used in the two published studies (Henriques & Davidson, 1997; Rabe, Debener, Brocke, & Beauducel, 2005 ) that have assessed the relationship of the DOTLOC task to depressive traits. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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Design
We (Shiffman & Jarvik, 1976) , and Beck Depression Inventory I (BDI; Beck, Steer, & Carbin, 1988; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961) score.
Procedure
Individuals interested in participating in the study were screened by phone and subsequent in-lab interviews, followed by consenting procedures. Urine psychoactive drug screening (Accutest® 10-MultiDrug Screen; Jant Pharmacal Corporation, Encino, CA), pregnancy tests (RapidVue®; Quidel Corporation, San Diego, CA), breath CO concentrations (Vitalograph® BreathCO Monitor; Vitalograph Inc, Lenexa, KS) were obtained at study onset and subsequently. Participants then completed a medical history form and were examined by a physician for medication-related risks.
During a practice session, the EEG data recording procedure was described and an actual sample recording was carried out so that participants could learn how head/eye movements and subtle muscle tension contaminate the EEG recordings, and thus how to minimize the movement-related artifacts. A short version of the DOTLOC task (see below) was also administered.
During the two experimental EEG sessions, BDI, craving to smoke, breath CO, saliva, and urine samples were obtained, followed by two repetitions of the 12-min DOTLOC task while EEG was recorded. The computerized DOTLOC task was similar to the one used in Henriques and Davidson (1997) and Rabe et al. (2005) . On each trial of the task, two white open rectangles of equal size were presented simultaneously on a black screen: one on the top right with two randomly separated dots inside, and the other on the bottom left with an array of variable numbers (32, 41, or 50 in total) . A trigger was sent to the EEG system to mark the onset of the two rectangles and a word "study" was shown for 2,700 ms during which participants studied the whole configuration on screen. The word respond replaced study and was shown for 1,000 ms, after which participants were instructed to mouse-click the two numbers that would be covered by the two dots if the top rectangle was superimposed onto the bottom rectangle. The computer recorded both numbers that were selected. Both repetitions of the task had three practice trials, with the first one having 60 experimental trials (20 trials for each of the three number array sizes) and the second one 61 different experimental trials (21 for each array size).
EEG Data Processing
The EEG data were first processed in Net Station 4.4.2 with a low-pass filter of 55 Hz to remove the electromagnetic field (EMF) frequencies, followed by a high-pass filter of 1.5 Hz to eliminate slow-drift artifacts. Then the data were exported to EEGLAB 13.3.2b (Swartz Center for Computational Neuroscience, University of California, San Diego, La Jolla, CA) running under a MATLAB® 2014 (MathWorks, Natick, MA) environment for further processing. Individualized head models were created for each participant and each experimental session from photogrammetric pictures and subsequently inserted into corresponding EEG files. The data were epoched from 400 ms to 2,448 ms (i.e., 2,048 ms long with 512 data points) after the onset of the "study" trigger.
EEG epochs contaminated by irregular events (e.g., those caused by a sneeze or movements) were removed by an EEGLAB frequency-based algorithm. The data of bad channels, defined as 4 SD from the averaged power of all channels, were reconstructed using a spherical spline interpolation from the data of surrounding channels. Few files (0.7%) had more than three (maximum of six) bad channels.
An average reference was computed from Cz-referenced data by subtracting the average over all electrodes from each electrode for each time point. Next, an Infomax ICA decomposition was performed to generate 45 independent components, which were further analyzed first by MARA 1.2 plugin (Winkler, Haufe, & Tangermann, 2011) to automatically remove artifactual components containing, for example, electrooculography (EOG) and electromyography (EMG), and then by CORRMAP 2.0.0 plugin (Viola et al., 2009 ) to semiautomatically remove electrocardiogram and residual EOG components. Finally, an automatic EMG correction method from the AAR 1.3 plugin (Gómez-Herrero et al., 2006) was used to clean any remaining EMG in the data.
A fast Fourier transformation was applied to all artifact-cleansed epochs and the power spectra across the 2,048 ms, and all epochs were averaged to generate a summary spectrum per participant, task repetition, and session (in practice, because the raw absolute EEG alpha power for two task repetitions was highly correlated in both Placebo [PLA] and Buproprian [BUP] groups, all rs Ͼ .92, ps Ͻ .001, the mean alpha power of the two repetitions was used to represent the power for that session). The total alpha (8 -13 Hz) power density (V 2 /Hz) was extracted from the spectrum for Channels F3, F4, P3, and P4; power asymmetry scores for the frontal and parietal areas were then calculated using the following formula:
, or specifically, ln(F4) -ln(F3) and ln(P4) -ln(P3). The natural log (ln) of EEG power density was used because untransformed power values tend to be positively skewed. As a result, a raw power less than 1 V 2 /Hz would be converted into a negative value. A positive asymmetry score indicates more power on the right side relative to the left side, and vice versa. Although data from only four electrodes of interest were reported in this article, calculations based on F3, F4, P3, and P4 and their nearest five neighboring channels (i.e., averaging over a cluster of channels in the four target brain regions) also revealed essentially the same results (data not shown).
Results

Group Characteristics
The results of relevant statistical tests (Fisher's exact tests for nominal variables, Mann-Whitney U tests for interval variables, and independent-samples t tests for continuous variables) revealed no differences between the PLA and BUP groups in sex, race, This document is copyrighted by the American Psychological Association or one of its allied publishers.
depression history, alcohol consumption, education, age, smoking, and so forth (all ps Ͼ .09; see Table 1 ). It should be noted that breath CO (for the detection of smoking) and self-reported daily cigarette use (data not shown here) indicated that the two groups did not smoke a different number of cigarettes before and after the 14-day treatment.
EEG Alpha Asymmetry
Given that the percentages of male and female participants in each treatment group were relatively equal, and that this study involved an antidepressant in smokers, an exploratory analysis of sex differences was first conducted. Specifically, the frontal and parietal hemispheric asymmetries (ln[R] -ln[L]) were computed and subjected to a 2 (Treatment: PLA vs. BUP) ϫ 2 (Session: PRE vs. POST) ϫ 2 (Region: Frontal vs. Parietal) ϫ 2 (Sex: Male vs. Female) mixed-design analysis of variance (ANOVA). Sex alone or its high-order interactions with any other variables did not affect asymmetries (all ps Ͼ .14). Therefore, sex was dropped as an independent variable from all the following analyses. Similarly, depression history or its interactions did not affect asymmetries (all ps Ͼ .23) and it was dropped as well. Furthermore, Sidak adjustment of p values was applied to multiple comparisons in the following analyses when appropriate.
The computed frontal and parietal hemispheric asymmetries (ln[R] -ln[L]) were subjected to a 2 (Treatment: PLA vs. BUP) ϫ 2 (Session: PRE vs. POST) ϫ 2 (Region: Frontal vs. Parietal) mixed-design ANOVA. There was a significant three-way (Treatment ϫ Session ϫ Region) interaction, F(1, 108) ϭ 4.72, MSE ϭ 0.54, p ϭ .03, p 2 ϭ .04, which was further examined with 2 two-way (Treatment ϫ Session) ANOVAs by breaking down Region.
Frontal alpha asymmetry. For the frontal area, there was not a significant main effect of Treatment, a main effect of Session, or their interaction (all ps Ͼ .11).
Parietal alpha asymmetry. For the parietal area, a significant interaction between Treatment and Session, F(1, 108) ϭ 4.35, MSE ϭ 0.51, p ϭ .04, p 2 ϭ .04, was found. The Treatment ϫ Session interaction was analyzed using a simple main effect analysis separately for each treatment group. The parietal EEG asymmetry in the PLA group did not change from PRE session (M ϭ 0.08, SE ϭ 0.05) to POST session (M ϭ 0.13, SE ϭ 0.05) (p ϭ .37), whereas the parietal EEG asymmetry in the BUP group tended to decrease from PRE session (M ϭ 0.21, SE ϭ 0.08) to POST session (M ϭ 0.04, SE ϭ 0.08) (p ϭ .06). Note that the PLA and BUP groups did not differ in parietal EEG asymmetry at PRE session (p ϭ .21; see Figure 1 ).
EEG Alpha Power
Because a reduction in the parietal EEG alpha asymmetry could be due either to a relative decrease in right parietal alpha power or to a relative increase in left parietal alpha power, a further fine analysis on alpha power directly was performed. Specifically, the natural logarithm of the alpha power of Channels F3, F4, P3, and P4 during the DOTLOC task was subjected to a 2 (Treatment: PLA vs. BUP) ϫ 2 (Session: PRE vs. POST) ϫ 2 (Region: Frontal vs. Parietal) ϫ 2 (Hemisphere: Left vs. Right) mixed-design ANOVA. There was a significant four-way interaction, F(1, 108) ϭ 4.72, MSE ϭ 0.27, p ϭ .03, p 2 ϭ .04 (see Table 2 ), which was further examined with 2 three-way ANOVAs by breaking down Region.
Frontal alpha power. The alpha power of the two frontal channels (F3, F4) was subjected to a 2 (Treatment) ϫ 2 (Session) ϫ 2 (Hemisphere) mixed-design ANOVA, where only a significant interaction between Treatment and Session, F(1, 108) ϭ 8.14, MSE ϭ 1.03, p ϭ .01, p 2 ϭ .07, was found. This interaction was then analyzed using a simple main effect analysis separately for each Group. Regardless of the Hemisphere, the frontal alpha power in the PLA group increased from PRE session (M ϭ Ϫ0.90, SE ϭ 0.10) to POST session (M ϭ Ϫ0.80, SE ϭ 0.11; p ϭ .02), whereas the frontal alpha power in the BUP group tended to decrease from PRE session (M ϭ Ϫ1.11, SE ϭ 0.17) to POST session (M ϭ Ϫ1.23, SE ϭ 0.17; p ϭ .07).
Parietal alpha power. The alpha power of the two parietal channels (P3, P4) was subjected to a 2 (Treatment) ϫ 2 (Session) ϫ 2 (Hemisphere) mixed-design ANOVA, where a significant three-way (Treatment ϫ Session ϫ Hemisphere) interaction was found, F(1, 108) ϭ 4.35, MSE ϭ 0.25, p ϭ .04, p 2 ϭ .04. This three-way interaction was further examined with 2 two-way (Oldfield, 1971) : Ϫ1 ϭ left handed; 1 ϭ right handed.
c The diagnosis of depression history was based on the Structural Clinical Interview. Participants reported two depressive episodes at most. This document is copyrighted by the American Psychological Association or one of its allied publishers.
(Treatment ϫ Session) ANOVAs by assessing changes within each hemisphere. For the left parietal area, there was a significant interaction between Treatment and Session, F(1, 108) ϭ 4.22, MSE ϭ 0.54, p ϭ .04, p 2 ϭ .04, which was then analyzed using a simple main effect analysis separately for each treatment group. The left parietal alpha power in the PLA group tended to increase from PRE session (M ϭ Ϫ0.93, SE ϭ 0.12) to POST session (M ϭ Ϫ0.82, SE ϭ 0.12; p ϭ .05), whereas the left parietal alpha power in the BUP group did not change from PRE session (M ϭ Ϫ1.19, SE ϭ 0.19) to POST session (M ϭ Ϫ1.30, SE ϭ 0.20; p ϭ .24).
For the right parietal area, there was again a significant interaction between Treatment and Session, F(1, 108) ϭ 27.75, MSE ϭ 2.09, p Ͻ .001, p 2 ϭ .20. The follow-up analysis showed that the right parietal alpha power in the PLA group increased from PRE session (M ϭ Ϫ0.85, SE ϭ 0.12) to POST session (M ϭ Ϫ0.69, SE ϭ 0.12; p Ͻ .001), whereas the right parietal alpha power in the BUP group decreased from PRE session (M ϭ Ϫ0.98, SE ϭ 0.19) to POST session (M ϭ Ϫ1.26, SE ϭ 0.19; p Ͻ .001).
In summary, from pre-to posttreatment, there was a global (left and right, frontal and parietal) increase in alpha power in the PLA group. In contrast, there was not such a global increase in the BUP group from PRE session to POST session; in fact, the pattern was reversed in the right (but not left) parietal area such that there was reduced right parietal alpha power when on BUP. Thus, the parietal asymmetry difference between treatments was due to BUP reducing right parietal alpha power (increasing right parietal activation), whereas PLA was associated with increased right parietal alpha power (decreasing right parietal activation). (The same left and right parietal alpha power data from Table 2 but without the natural logarithm transformation were plotted in Figure 2 for an easy visualization of the results.)
BDI Scores, Craving to Smoke, and Task Accuracy
Participants' BDI scores, craving to smoke, and task accuracy were subjected to three separate 2 (Treatment: PLA vs. BUP) ϫ 2 (Session: PRE vs. POST) mixed-design ANOVAs. The BDI results showed that there was no main effect of Treatment, F(1, Similar to the calculation of EEG alpha power, the DOTLOC task accuracy on the two repetitions was also highly correlated in both PLA and BUP groups (all rs Ͼ .90, ps Ͻ .001). Therefore, the mean accuracy of the two repetitions was computed and used to represent the accuracy for that session. The task accuracy results indicated that regardless of Treatment, participants' task accuracy increased from PRE session (M ϭ .76, SE ϭ .02) to POST session (M ϭ .81, SE ϭ .02) , F(1, 108) 
Individual Differences in Drug Response
In order to investigate individual differences in response to bupropion treatment, the BUP group was dichotomized based on parietal alpha asymmetry at PRE session. We then examined whether the resultant two BUP subgroups would differ in acrosssession changes in parietal asymmetry, BDI, and task accuracy.
Specifically, the BUP group was divided into two subgroups (Negative vs. Positive) based on the parietal asymmetry at PRE session with zero as the cut-off point, resulting in 14 participants in the Negative BUP subgroup and 17 in the Positive BUP subgroup. Then, the parietal asymmetry was subjected to a 2 (BUP Subgroup: Negative vs. Positive) ϫ 2 (Session: PRE vs. POST) mixed-design ANOVA. Not surprisingly, the Negative BUP subgroup (M ϭ Ϫ0.13, SE ϭ 0.10) had lower parietal asymmetry than the Positive BUP subgroup (M ϭ 0.34, SE ϭ 0.09) regardless of Session, F(1, 29) ϭ 11.23, MSE ϭ 3.36, p ϭ .002, p 2 ϭ .28. The parietal asymmetry did not change from PRE session (M ϭ 0.17, SE ϭ 0.08) to POST session (M ϭ 0.03, SE ϭ 0.08) regardless of BUP Subgroup, F(1, 29) ϭ 3.34, MSE ϭ 0.28, p ϭ .08, p 2 ϭ .10. Critically, there was a significant interaction between BUP Subgroup and Session, F(1, 29) ϭ 16.81, MSE ϭ 1.40, p Ͻ .001, p 2 ϭ .37, such that the parietal asymmetry in the Negative BUP subgroup did not change from PRE session (M ϭ Ϫ0.22, SE ϭ 0.12) to POST session (M ϭ Ϫ0.05, SE ϭ 0.11; p ϭ .14), whereas the parietal symmetry in the Positive BUP subgroup was significantly decreased from PRE session (M ϭ 0.55, SE ϭ 0.11) to POST session (M ϭ 0.12, SE ϭ 0.10; p Ͻ .001). As shown in Figure 3 , only 4 out of the 14 participants (28.6%) in the Negative BUP subgroup experienced a parietal asymmetry decrease across Session, whereas 16 out of the 17 participants (94.1%) in the Positive BUP subgroup decreased.
BDI scores and craving to smoke did not differ between BUP subgroups, or change across Session, or vary as an interaction of BUP Subgroup and Session (all ps Ͼ .11). Task accuracy increased from PRE session (M ϭ .76, SE ϭ .03) to POST session (M ϭ .81, SE ϭ .03) regardless of BUP Subgroup, F(1, 29) ϭ 10.69, MSE ϭ 0.04, p ϭ .003, p 2 ϭ .27, but it did not differ between BUP subgroups, or vary as an interaction of BUP Subgroup and Session (ps Ͼ .26).
Discussion
To the best of our knowledge, the present study is the first reported study to have examined the effects of bupropion on task-related EEG measures. The main findings included the following: (a) bupropion (vs. placebo) treatment reduced parietal EEG alpha asymmetry (primarily by reducing right parietal alpha power), which has been associated with a decrease in depressive symptoms according to previous studies (Henriques & Davidson, 1997; Rabe et al., 2005) ; (b) within the bupropion group, participants who had greater right-sided parietal deactivation (i.e., more right vs. left parietal alpha power as previously seen in depressionprone individuals) at pretreatment exhibited a larger reduction in their depressive EEG pattern at posttreatment; and (c) BDI scores, craving to smoke, and task accuracy did not (differentially) change in the bupropion group relative to the placebo group. Overall, the findings support the hypothesis that visuospatial task-related parietal alpha power asymmetry is a sensitive biomarker of bupropion's effects, and that changes in this asymmetry index can be observed without concurrent changes in self-reported mood or task performance. The individual change of parietal alpha asymmetry from the pretreatment to posttreatment session within the Bupropion group, shown separately for participants who had a negative pretreatment asymmetry (n ϭ 14) and who had a positive pretreatment asymmetry (n ϭ 17). Each line represents a participant. The parietal asymmetry in the Negative Bupropion subgroup did not change with treatment, whereas the parietal asymmetry in the Positive Bupropion subgroup was significantly decreased. Because the exclusion of one outlier in the Positive Bupropion subgroup (shown at the top of the right panel) did not change the subgrouping statistical significance, the outlier was included in the subgrouping analyses reported in the text. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Bupropion's Effects on EEG Asymmetry and Alpha Power
The above-noted EEG asymmetry results are coupled with underlying variations in alpha power (see Table 2 ) such that the placebo group had a global (left and right, frontal and parietal) increase in alpha power across sessions, whereas the bupropion group had stable alpha power across sessions in left parietal areas but a reduction in the right parietal area. The global increase in alpha power (and associated decrease in cortical activation) in the placebo group might be due to the participants' increased familiarity with the experimental task (they essentially performed the same task in two sessions, though task trial orders were randomized) and to generalized adaptation to the assessment settings; indeed, studies have demonstrated that prolonged exposure to monotonous conditions leads to an increase in alpha power in the EEG spectrum (Kiroi & Aslanyan, 2006) . Given that the same familiarity (and thus the tendency to increase alpha power) was also likely to have occurred in the bupropion group, bupropion actually decreased alpha power (or increased cortical activity)-in a relative sense-over the whole brain (the greater reduction in right parietal alpha power is to be discussed in the next paragraph). Siepmann et al. (2005) reported in their study that a 14-day bupropion administration also diminished resting-state alpha power. Taken together, bupropion may act like a psychostimulant that is able to reduce alpha power (increase cortical activity) at rest and during the present visuospatial task.
How did bupropion (vs. placebo) treatment reduce EEG alpha power to the same extent in the left and right frontal areas, but to a greater extent in the right parietal area than in the left parietal area during the visuospatial task? The Quadrant Model of depression (Campbell, Hill, & Podd, 2011; Heller & Nitscke, 1997 ; see also Shenal, Harrison, & Demaree, 2003) posits that the brain could be divided into four quadrants (left frontal, right frontal, left parietal, and right parietal), and that deficits in any of the four quadrants can result in impaired or biased cognitive processing associated with depression. Depression features higher left-versusright frontal alpha power during emotional tasks (Schaffer et al., 1983; Stewart et al., 2014) . It has been argued that this pattern can be understood with the idea that the left frontal quadrant is involved in approach behaviors and the right frontal in withdrawal behaviors, such that the withdrawal symptoms in depression are related to a relative hypoactivation in the left frontal quadrant (Stewart et al., 2014) . It is possible that bupropion, as an antidepressant, had reduced alpha power (increased cortical activity) to a greater extent in the left than right frontal area, yet because the two frontal quadrants are more involved in emotional processing, the potential differential/asymmetric frontal alpha reduction due to bupropion treatment was not elicited by the present visuospatial task that mainly taps the right parietal functioning.
Although the role of left parietal quadrant in depression is not well understood (perhaps not impaired or less impaired), depression has been consistently associated with cognitive deficits in the right parietal quadrant, such as impairment in visuospatial processing, interpreting nonverbal (facial expression and gesture) information, and heuristic and intuitive decision making that are associated with right parietal functioning (reviewed by Heller & Nitscke, 1997) , such that depressed (vs. healthy) individuals are more likely to perform worse on relevant tasks and have reduced right parietal reactivity and activation (i.e., higher alpha power; e.g., Henriques & Davidson, 1997) . Therefore, the right (vs. left) parietal quadrant might be more susceptible to bupropion's antidepressant effects and thus show a greater alpha power reduction (cortical activity augmentation) during the visuospatial task.
BDI, Craving to Smoke, and Task Accuracy
Bupropion (vs. placebo) did not change BDI scores, craving to smoke, or affect Dot Localization task accuracy differently (the accuracy in both treatment groups was improved to the same extent, possibly due to the learning effect). This resulting pattern suggests that EEG measurement is more sensitive to early and subtle responses to the 14-day bupropion's antidepressant treatment, though it is also possible that floor (low BDI scores at pretreatment) and ceiling (high task accuracy at posttreatment) effects might have played a role in detecting effects of bupropion.
Individual Differences in Response to Bupropion
Although the overall bupropion group showed a reduction in the parietal asymmetry across sessions, additional analyses were conducted to investigate individual differences in response to bupropion treatment. Specifically, the negative and positive (in reference to a parietal asymmetry of zero at pretreatment) bupropion subgroups were constructed. Despite no subgroup differences in changes in BDI scores, craving to smoke, and task accuracy, the positive bupropion subgroup exhibited a significant drop in the parietal asymmetry across sessions, whereas the negative bupropion subgroup maintained the same levels. In fact, a participant with an initial positive parietal asymmetry was three times (94.1% vs. 28.6%) as likely to experience a parietal asymmetry decrease with bupropion treatment as a participant with an initial negative parietal asymmetry.
Limitations and Conclusions
There are a number of limitations to the present study, such as the modest sample size, limited treatment duration, and lack of clinically depressed individuals, nonsmokers, and substance abusers. These limitations restrict generalization of current findings to these populations. Future studies addressing these limitations are called for, given the promising findings of the current investigation. For example, longer-duration studies will be valuable in assessing how the parietal alpha asymmetry and individual differences in parietal alpha asymmetry relate to changes in subjective and behavioral depression measures, considering the general time lag of 3-5 weeks for bupropion to exert its subjective and behavioral antidepressant effects (Fabre et al., 1983; Lineberry et al., 1990) . Also, depressed individuals should likely be recruited in order to characterize bupropion's EEG effects related to changes in clinical depression. Similarly, nonsmoking participants are needed to tease apart the influence of smoking/nicotine and bupropion on EEG, given that nicotine per se also has antidepressant properties and shows asymmetric EEG effects (Knott, Thompson, Shah, & Ilivitsky, 2012) and that smokers (vs. nonsmokers) may exhibit different EEG asymmetry patterns (Knott et al., 2013) .
Finally, because the visuospatial task in the present study is especially sensitive to the measure of parietal asymmetry, new This document is copyrighted by the American Psychological Association or one of its allied publishers.
EEG data from resting state and emotional tasks that are instead specific to the frontal asymmetry (Schaffer et al., 1983; Stewart et al., 2014) would likely provide complementary findings in the frontal brain areas related to the effects of bupropion. Indeed, Bares et al. (2010) found that the change in the frontal theta cordance at rest after bupropion treatment could be potentially correlated with activity changes in anterior cingulate and prefrontal cortices. Despite these limitations, the findings that a subchronic (14 days) treatment of bupropion reduced parietal EEG asymmetry and the right parietal alpha power per se during a visuospatial task in healthy smokers prior to quitting are novel in the sparse literature regarding the effects of bupropion on brain activity and represent a valuable step forward toward the characterization of bupropion's effects, including possible therapeutic mechanisms as an antidepressant and a smoking cessation aid.
